The effect of comorbidities on the choice of tyrosine kinase inhibitors in patients with chronic myeloid leukemia
{{output}}
Tyrosine kinase inhibitors (TKIs) approved for chronic myeloid leukemia known to have similar efficacies but different safety profiles. Therefore, the choice of patient-specific treatments is driven by factors such as tolerability and adverse event profile of ... ...
